IMIBIC Enlace externo is a health research institute founded on 24 August 2008 following an agreement between the Consejería de Salud, the Consejería de Innovación, Ciencia y Empresa of the Junta de Andalucía (the regional Department of Health, the regional Department of Innovation, Science and Business of the Andalusian Regional Government), and the University of Córdoba, signed on 29 July 2007.

IMIBIC works in collaboration with the University of Córdoba and the Reina Sofía University Hospital, a public hospital with a high level of care and strongly committed to the training of health professionals.

IMIBIC is managed by the Fundación para la Investigación Biomédica de Córdoba (FIBICO, Córdoba Foundation for Biomedical Research), founded on 27 December, 2007.

Our group is part of the Scientific Program on Chronic and Inflammatory Diseases, oriented to the study of the various chronic processes of modern society, with special emphasis on those of an inflammatory and autoimmune nature.

This area mainly covers the study of chronic autoimmune and systemic autoimmune diseases, cardiovascular diseases, neurological diseases, renal and urological diseases, liver and digestive diseases.

Our research team GC-5 Systemic Autoimmune Diseases and Chronic Arthropaties, employs synergistically clinical-therapeutic approaches and cellular and molecular approaches, and has as main objectives:

  1. Analyse molecular and cellular mechanisms of atherothrombosis development in systemic autoimmune diseases (EAS), and identify biomarkers and regulatory mechanisms promoted by new therapeutic approaches
  2. Analyse the role of the chronic systemic inflammation in the glucose and lipid metabolism in rheumatoid and psoriatic arthritis
  3. Study of the effects of conventional therapies (DMARDs), new agents (Apremilast) and other biologic drugs (anti-TNFa) on the metabolic syndrome associated with chronic inflammatory diseases
  4. Record, describe, and analyze clinical, epidemiological, demographic, genetic, radiographic, pathophysiological and of therapeutic response in patients with spondyloarthritis (AS) in Spain.
  5. Design, develop and validate a new system of measurement of mobility (most important expression of structural damage) of AS patients.